ARVN Arvinas Corp: Rasio Kapitalisasi Pasar marang Nilai Buku

Arvinas, Inc. (ARVN) is a PROTAC innovator developing oral drugs to combat prostate and breast tumors that are more effective than traditional chemotherapy. The price trend reflected below on GURU.Markets at the value of 0.89 links the company's technological success to royalty revenues and payments from Bayer and Pfizer. The biotech firm is currently finalizing the late-stage clinical trials of its breakthrough developments.

Arvinas, Inc. (ARVN) - Rasio Kapitalisasi Pasar marang Nilai Buku saka 04.07.2022 nganti 29.10.2026

ARVN (Arvinas Inc): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:

Bagan rega Arvinas, Inc.|ARVN - Prakiraan gabungan firma investasi

- data kapitalisasi pasar:

Kapitalisasi pasar Arvinas Corp|ARVN - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Buku saben Saham Arvinas|ARVN - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku arvinas.com|ARVN - Total Aset Bisnis

- data utang lan likuiditas:

Total Utang marang Modal Arvinas, Inc.|ARVN - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Arvinas Corp|ARVN - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Arvinas Corp|ARVN - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Arvinas

Pambiji fundamental:ARVN (Arvinas, Inc.)

Arvinas, Inc. (ARVN) status as a developer of unique protein degradation methods lays the foundation for future pricing power, which often leads to a significant market value premium over tangible assets. This ratio, illustrated on the market-to-book value chart, compares market capitalization with net assets, allowing investors to assess the extent to which the business is overvalued relative to its material base.